M2 PHARMA-August 30, 2019-SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid
Differential diagnosis of tumor arising from rectus sheath including desmoid
tumor, hematoma, and infection. The most common tumor arising from rectus sheath is desmoid
Nirogacestat, our gamma secretase inhibitor for the treatment of desmoid
tumors is currently in a Phase 3 clinical trial, and SpringWorks Therapeutics expects to initiate a Phase 2b study of PD-0325901, our MEK 1/2 inhibitor for neurofibromatosis type 1 patients with plexiform neurofibromas, in the third quarter of 2019.
In 2002, the World Health Organization used the term 'desmoid-type fibromatosis' for deep fibromatosis  which is usually called a desmoid
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced yesterday that it has dosed its first patient in the phase three 'DeFi' (Desmoid/Fibromatosis) trial, assessing nirogacestat, an oral, selective, small molecule gamma-secretase inhibitor, in adult patients with progressing desmoid
tumors constitute a less aggressive form of fibromatosis, originating from muscle and aponeurosis.
Global Banking News-November 7, 2018-SpringWorks Therapeutics announces grant of FDA Fast Track designation for Nirogacestat to treat desmoid
tumours in adult patients
Differential Diagnoses: stitch granuloma, neoplasm, neuroma, hematoma, desmoid
tumor, abscess, lymphadenopathy.
The differential diagnoses6 that should be considered with CFPTs are desmoid
tumours, solitary fibrous tumour, desmoplastic fibroblastoma, calcifying aponeurotic fibroma, collagenous fibroma and other sub categories of inflammatory pseudotumours (focal myositis, plasma cell granuloma, inflammatory myofibroblastic tumour etc).6 The diagnosis of CFPT requires clinical exclusion of neoplasms and absence of active infectious processes.
In February 2014, tests showed O'Connell was suffering from large desmoid
tumor which had grown "in an unchecked and unobserved manner" because Antabli failed to order diagnostic testing, O'Connell's amended complaint said.
tumors (DTs) of the head and neck have typically been classified as extra-abdominal, although the anatomic challenges of the head and neck warrant consideration of these DTs as a special entity.
tumors of the head and neck a clinical study of a rare entity.